Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-3-[18F]Fluoro-2-Methylpropanoic Acid (FAMP) and (R)- and (S)-3-[18F]Fluoro-2-Methyl-2-N-(Methylamino)propanoic Acid (NMeFAMP) as Potential PET Radioligands for Imaging Brain Tumors
摘要:
The non-natural amino acids (R)- and (S)-2-amino-3-fluoro-2-methylpropanoic acid 5 and (R)- and (S)-3-fluoro-2-methyl-2-N-(methylamino)propanoic acid 8 were synthesized in shorter reaction sequences than in the original report starting from enantiomerically pure (S)- and (R)-alpha-methyl-serine, respectively. The reaction sequence provided the Cyclic sulfamidate precursors for radiosynthesis or (R)- and (S)-[F-18]5 and (R)- and (S)-[F-18]8 in fewer steps than in the original report. (R)- and (S)-[F-18]5 and (R)- and (S)-[F-18]8 were synthesized by no-carrier-added nucleophilic [F-18]fluorination in 52-66% decay-corrected yields with radiochemical purity over 99%. The cell assays showed that all four compounds were substrates for amino acid transport and enter 9L rat gliosarcoma cells in vitro at least in part by system A amino acid transport, The biodistribution Studies demonstrated that in vivo tumor to normal brain ratios for all compounds were high with ratios of 20:1 to 115:1 in rats with intracranial 9L tumors. The (R)-enantiomers of [F-18]5 and [F-18]8 demonstrated higher tumor uptake in vivo compared to the (S)-enantiomers.
Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-3-[18F]Fluoro-2-Methylpropanoic Acid (FAMP) and (R)- and (S)-3-[18F]Fluoro-2-Methyl-2-N-(Methylamino)propanoic Acid (NMeFAMP) as Potential PET Radioligands for Imaging Brain Tumors
摘要:
The non-natural amino acids (R)- and (S)-2-amino-3-fluoro-2-methylpropanoic acid 5 and (R)- and (S)-3-fluoro-2-methyl-2-N-(methylamino)propanoic acid 8 were synthesized in shorter reaction sequences than in the original report starting from enantiomerically pure (S)- and (R)-alpha-methyl-serine, respectively. The reaction sequence provided the Cyclic sulfamidate precursors for radiosynthesis or (R)- and (S)-[F-18]5 and (R)- and (S)-[F-18]8 in fewer steps than in the original report. (R)- and (S)-[F-18]5 and (R)- and (S)-[F-18]8 were synthesized by no-carrier-added nucleophilic [F-18]fluorination in 52-66% decay-corrected yields with radiochemical purity over 99%. The cell assays showed that all four compounds were substrates for amino acid transport and enter 9L rat gliosarcoma cells in vitro at least in part by system A amino acid transport, The biodistribution Studies demonstrated that in vivo tumor to normal brain ratios for all compounds were high with ratios of 20:1 to 115:1 in rats with intracranial 9L tumors. The (R)-enantiomers of [F-18]5 and [F-18]8 demonstrated higher tumor uptake in vivo compared to the (S)-enantiomers.